India’s NPPA Cracks Down On Unapproved Fixed-Dose Combos
This article was originally published in PharmAsia News
Executive Summary
Continuing with measures to streamline pricing norms in the Indian pharma industry, the country’s drug price watchdog has in its latest move warned of fines and prosecution if unapproved fixed-dose combinations are found in the market.